Enroll-HD

Pubblicazioni

Pubblicazioni che sfruttano dati, campioni biologici e/o infrastrutture Enroll-HD.

Pubblicazioni

Enroll-HD è sia uno studio osservazionale mondiale che una piattaforma di ricerca clinica che supporta vari studi e sperimentazioni, con l’obiettivo generale di accelerare lo sviluppo terapeutico della MH. I dati clinici e i campioni biologici raccolti in Enroll-HD e in altri studi sulla MH vengono resi disponibili attraverso la piattaforma Enroll-HD a qualsiasi ricercatore verificato secondo le modalità Politica di accesso ai dati clinici e ai campioni biologici per estrarre quanta più conoscenza possibile. Come sempre, siamo enormemente grati alle migliaia di partecipanti e famiglie in tutto il mondo che donano altruisticamente tempo ed energia, nonché allo staff dedicato dei centri clinici che rende possibile Enroll-HD.

Quando pubblicano i loro risultati, i ricercatori che utilizzano questi dati e campioni biologici sono tenuti a rispettare le norme Politica di pubblicazione Enroll-HD, compreso il pieno riconoscimento delle persone che hanno contribuito alla raccolta dei dati Enroll-HD. Le pubblicazioni ospitate qui hanno tutte utilizzato i set di dati Enroll-HD che vengono periodicamente resi disponibili e illustrano alcune delle aree di ricerca sulla MH che Enroll-HD sta influenzando direttamente.

Se la tua pubblicazione che utilizza i dati Enroll-HD non è inclusa in questa galleria o sei a conoscenza di una pubblicazione che dovrebbe essere inclusa, faccelo sapere all'indirizzo info@chdifoundation.org.

Authors

Title

Journal

Braun AA, Buff J, Moser NH, Sassenburg R, Briel N, Maric A, Schreiner SJ, Jung HH

Phase-targeted auditory stimulation enhances slow-wave activity during sleep in Huntington's disease: A pilot crossover study
J Huntingtons Dis
Nov 01, 2026
15 (4) :641-652
PMID: 42393845

Halabi N, Killoran A, Nopoulos PC

Effect of Vesicular Monoamine Transporter Type-2 Inhibitors on Motor Features in HD
MedRxiv [Preprint]
Set 28, 2026
PMID: 42856384
PMCID: 13648754

Lunven M, Van Den Enden P, Gil Salcedo A, Pertzov Y, Bapst B, Youssov K, Morgado G, Busse M, Massart R, Rosser A, Bachoud-Lévi AC

Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates
J Neurol Neurosurg Psychiatry
Set 14, 2026
97 (10) :873-881
PMID: 42386504
PMCID: 13638334

Jacob SS, Langbehn DR, Stolwyk RJ, Stout JC

The Trail Making Test in healthy controls and Huntington's disease: Demographic effects and normative tables based on a large data set
Psychol Assess
Set 10, 2026
PMID: 42721334

Gao Y, Ásbjörnsdóttir B, Vinther-Jensen T, Von Essen MR, Hellem MNN, Hjermind LE, Ejlerskov P, Landwehrmeyer GB, Sellebjerg F, Nielsen JE, Lewerenz J

CSF leukocytes transiently increase before onset of Huntington disease in association With a stage-specific CSF cytokine/chemokine pattern
Neurol Neuroimmunol Neuroinflamm
Set 01, 2026
13 (5) :e200632
PMID: 42607284
PMCID: 13485137

Jeyakumar N, Woolnough D, Li G, Teixeira-Pinto A, Jeyakumar V, Loy CT

A novel machine learning approach for the classification of Huntington disease manifestation using motor features
Parkinsonism Relat Disord
Set 01, 2026
150 :108851
PMID: 42497610

Mclauchlan D, Drew C, Holmans P, Rosser A

Exploring the association between antidepressants, progression and mortality in Huntington's disease
Brain
Ago 03, 2026
149 (8) :2680-2688
PMID: 41564085
PMCID: 13431818

Demmin DL, Roché MW, Vaidya JG, Langbehn DR, Fuller RL, Weingast SZ, Sampaio C, Stebbins GT

A clinimetric evaluation of the problem behaviors assessment short form (PBA-s) within the context of the Huntington's disease integrated staging system (HD-ISS)
J Huntingtons Dis
Ago 01, 2026
15 (3) :468-475
PMID: 41787864

Kaddoura A, Dalbro SEJ, van Walsem MR, Pihlstrøm L

Assessing the prognostic value of early oculomotor abnormalities in Huntington's disease
Front Neurol
Giu 15, 2026
17 :1844433
PMID: 42376453
PMCID: 13310781

Franch-Marti C, Puig-Davi A, Rodriguez-Antiguedad J, Perez-Perez J, Olmedo-Saura G, Ruiz-Barrio I, Bojtos L, Perez-Carasol L, Tort-Merino A, Pagonabarraga J, Kulisevsky J, Martinez-Horta S

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease
Brain Commun
Giu 04, 2026
8 (3) :fcag210
PMID: 42339152
PMCID: 13284418

Heyd M, Landwehrmeyer GB, Lewerenz J

The pathological Huntingtin CAG triplet expansion differentially affects the diagnosis of systemic and organ-specific autoimmune diseases
Front Immunol
Mag 08, 2026
17
PMID: 42183198
PMCID: 13194399

Vazquez JE, Lin D, Mendizabal A, Ogilvie AC, Stuart EA, Garcia TP

Higher educational attainment in Huntington disease families: evidence from the Enroll-HD study
Orphanet J Rare Dis
Apr 09, 2026
21 (1) :142
PMID: 41957667

Gil-Salcedo A, Massart R, Youssov K, Morgado G, Bachoud-Levi AC

Profiles of patients at early stages of Huntington's disease based on the routine biological markers and the disease progression
J Neurol
Apr 02, 2026
273 (4) :249
PMID: 41928019
PMCID: 13046660

Roiboit CM, Langbehn DR, Stout JC

Minimal clinically important difference on cognitive measures for Huntington's disease using function as an anchor
Mov Disord
Apr 01, 2026
41 (4) :870-880
PMID: 41631759

Yao J, Feng G, Shao G, Wang Z, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM

Interplay between sex and cytosine-adenine-guanine-age product score in Huntington's disease: Clinical and neuroimaging perspectives
Mov Disord
Feb 01, 2026
41 (2) :489-499
PMID: 40985165
PMCID: 12951279

Hemicker G, Schwarzová K, Labrecque S, Cerejo C, Carbone F, Peball M, Wimmer B, Mahlknecht P, Krismer F, Djamshidian A, Seppi K, Heim B

Bridging the gap: sex-specific differences in Huntington's disease
Orphanet J Rare Dis
Gen 10, 2026
21 (1) :46
PMID: 41520110
PMCID: 12882381

Lee SH, Richardson BD, Ma Y, Marder KS, Garcia TP

SPARCC: Semi-Parametric Robust Estimation in a Right-Censored Covariate Model
J Am Stat Assoc
Gen 02, 2026
PMID: 41878319
PMCID: 13008303

Witkowski G, Zielonka D, Rola R, Sienkiewicz-Jarosz H

The association between smoking and Huntington's disease symptom onset and progression - results from Enroll-HD: The observational cohort study of people with Huntington's disease
Neurol Neurochir Pol
Gen 01, 2026
60 (1) :83-91
PMID: 41084856

Knights H, Coleman A, Farag M, Leocadi M, Murphy M, Fayer K, Thackeray O, Langbehn D, Hobbs N, Tabrizi SJ, Scahill RI, HD-YAS investigators

Bias in HD-ISS staging introduced by the FreeSurfer cross-sectional stream: Insights from the Huntington's Disease Young Adult Study (HD-YAS)
J Huntingtons Dis
Nov 01, 2025
14 (4) :396-402
PMID: 40801894
PMCID: 12602721

Garcia-Forn M, Castany-Pladevall C, Creus-Muncunill J, Golbano A, Escaramís G, Pérez-Pérez J, Balantzategi U, Hernan-Godoy M, Brito V, Kulisevsky J, Martí E, Pérez-Navarro E

Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients
Neurotherapeutics
Ott 01, 2025
22 (6) :e00716
PMID: 40774881

Di Cecca A, Ilardi CR, Della Pia F, Criscuolo C, Della Sala S, Salvatore E

Distortion errors characterise visuo-constructive performance in Huntington's disease
Clin Neuropsychol
Ago 01, 2025
39 (6) :1615-1633
PMID: 39394675

Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects
Nat Genet
Giu 01, 2025
57 (6) :1426-1436
PMID: 40490511

Stimming EF, Claassen DO, Sen GP, Klepitskaya O, Serbin M, Kim H, Hinton SC, Haubenberger D

Longitudinal treatment patterns of chorea in North American patients with Huntington's disease: Data from Enroll-HD
Neurol Ther
Giu 01, 2025
14 (3) :743-756
PMID: 39815077
PMCID: 12089624

Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS

Modeling disease progression and placebo response in Huntington disease: Insights from Enroll-HD and GENERATION HD1 cohorts
Neurology
Mag 27, 2025
104 (10) :e213646
PMID: 40315394
PMCID: 12057022

Bakels HS, van der Zwaan KF, Van Zwet E, Reijntjes R, Sprenger GP, Knecht TA, Roos RAC, de Bot ST

Comparison of the clinical spectrum of juvenile- and adult-onset Huntington disease: A national cohort and Enroll-HD observational study
Neurology
Mag 27, 2025
104 (10) :e213525
PMID: 40262071
PMCID: 12015966

Geva M, Goldberg YP, Schuring H, Tan AM, Long JD, Hayden MR

Antidopaminergic medications and clinical changes in measures of Huntington's disease: A causal analysis
Mov Disord
Mag 01, 2025
40 (5) :928-937
PMID: 40099482
PMCID: 12089908

Halabi N, Killoran A, Nopoulos PC, Schultz JL

Differentiating hyperkinetic and hypokinetic motor features in the progression of Huntington's disease
MedRxiv [Preprint]
Apr 21, 2025
PMID: 40313299
PMCID: 12045443

Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Levi AC

Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease
J Neurol
Feb 22, 2025
272 (3) :224
PMID: 39985726
PMCID: 11846732

Khetarpal V, Herbst T, Dominguez C, Munoz-Sanjuan I, Sampaio C, Marks B, Miller D, Farnham J, Ledvina A, Anglehart H, Rehmani I, LaFayette A, Spridco N, Langbehn D, Wild EJ, Pacifici R

Lack of evidence for kynurenine pathway dysfunction in Huntington’s disease: Cerebrospinal fluid and plasma analyses from the HDClarity study
J Huntingtons Dis
Feb 01, 2025
14 (1) :85-92
PMID: 39906760
PMCID: 7617368

van der Zwaan KF, Feleus S, Dekkers OM, Roos RAC, de Bot ST

Total functioning capacity scale in Huntington's disease: natural course over time
J Neurol
Gen 15, 2025
272 (2) :140
PMID: 39812810

Feleus S, Vo MTD, Kuijper LCM, Roos RAC, de Bot ST

Cognitive impairment predicts medication discrepancies in Huntington's disease: patient self-report compared to pharmacy records
J Neurol
Gen 02, 2025
272 (1) :55
PMID: 39665851

Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC

β-blocker use and delayed onset and progression of Huntington disease
JAMA Neurol
Gen 01, 2025
82 (1) :85-92
PMID: 39621338
PMCID: 11612910

Feleus S, Skotnicki LEM, Roos RAC, de Bot ST

Medication use and treatment indications in Huntington's disease; analyses from a large cohort
Mov Disord Clin Pract
Dic 19, 2024
11 (12) :1530-1541
PMID: 39431460

Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, Bentivoglio AR

Neuroleptic malignant syndrome in Huntington disease
Eur J Neurol
Dic 01, 2024
31 (12) :e16442
PMID: 39444167
PMCID: 11554869

Pollard A, Greetham D, Myatt J, Rickards H, Stanley C, Dungate D

Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK
R Soc Open Sci
Nov 20, 2024
11 (11) :240824
PMID: 39569347
PMCID: 11576117

Yao J, Feng B S G, Shao M S G, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM

Interplay between sex and disease burden in Huntington's disease: Clinical and neuroimaging perspectives
MedRxiv [Preprint]
Nov 02, 2024
PMID: 39574844
PMCID: 11581089

Gray SM, Dai J, Smith AC, Beckley JT, Rahmati N, Lewis MC, Quirk MC

Changes in 24(S)-hydroxycholesterol are associated with cognitive performance in early Huntington's disease: Data from the TRACK and ENROLL HD cohorts
J Huntingtons Dis
Nov 01, 2024
13 (4) :449-465
PMID: 39269850

Mendizabal A, Ogilvie AC, Bordelon Y, Perlman SL, Brown A

Racial disparities in time to Huntington disease diagnosis in North America: An Enroll-HD analysis
Neurol Clin Pract
Ott 01, 2024
14 (5) :e200344
PMID: 39872293
PMCID: 11771962

Mills JA, Long JD, Vaidya JG, Gantman EC, Sathe S, Tabrizi SJ, Sampaio C

Time to functional loss as an endpoint in Huntington's disease trials: Enrichment and sample size
Mov Disord
Ott 01, 2024
39 (10) :1809-1816
PMID: 39101272

Guzauskas GF, Tabrizi SJ, Long JD, Arnesen A, Hamilton JL, Claassen DO, Munetsi LR, Malik S, Rodríguez-Santana I, Ali TM, Zhang F

Long-term health outcomes of Huntington disease and the impact of future disease-modifying treatments: A decision-modeling analysis
Neurol Clin Pract
Ott 01, 2024
14 (5) :e200340
PMID: 39161748
PMCID: 11332983
it_ITIT

Piattaforma di ricerca clinica

Enroll-HD è una piattaforma di ricerca clinica e il più grande studio osservazionale al mondo per le famiglie della malattia di Huntington.

Per i centri dello studio

Prossimamente! Risorse operative per i siti di studio, compreso l'accesso al portale di formazione.